Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases

Clinical trial NCT03457948 · ACTIVE_NOT_RECRUITING

Trial details

NCT number

NCT03457948

Sponsor

Nicholas Fidelman, MD

Status

ACTIVE_NOT_RECRUITING

Phase

Phase 2

Study type

INTERVENTIONAL

Start date

2018-08-27

Primary completion

2025-07-31

Enrollment

32

View on ClinicalTrials.gov